Evidence map›Paper›PMID 27028855›Full record

ArticleOncotarget2016

Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas.

Marjolijn D Trietsch, Maaike H M Oonk, Lukas J A C Hawinkels, Rosalie Bor, Jaap D H van Eendenburg, Zina Ivanova, Alexander A W Peters, Hans W Nijman, Katja N Gaarenstroom, Tjalling Bosse

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Endoglin and squamous cell carcinomas.Frontiers in medicine · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Marjolijn D TrietschDepartment of Pathology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Maaike H M OonkDepartment of Gynaecology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
Lukas J A C HawinkelsGastroenterology-Hepatology and Molecular Cell Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Rosalie BorGastroenterology-Hepatology and Molecular Cell Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Jaap D H van EendenburgDepartment of Pathology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Zina IvanovaInstitute for Pathology and Parasitology, Bulgarian Academy of Sciences, 1040 Sofia, Bulgaria.
Alexander A W PetersDepartment of Gynaecology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Hans W NijmanDepartment of Gynaecology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands.
Katja N GaarenstroomDepartment of Gynaecology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Tjalling BosseDepartment of Pathology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Leiden University Medical Center · NLUniversity Medical Center Groningen · NLBulgarian Academy of Sciences · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVulvar cancer treatment is mostly curative, but also has high morbidity rates. In a search for markers that can identify patients at risk of metastases, we investigated the prognostic value of L1-cell adhesion molecule (L1CAM) in large series of vulvar squamous cell carcinomas (VSCCs). L1CAM promotes cell motility and is an emerging prognostic factor for metastasis in many cancer subtypes.

resultsL1CAM expression was observed at the invasive front or in spray-patterned parts of 17% of the tumours. L1CAM-positive tumours expressed vimentin more often, but L1CAM expression was not associated with TP53 or CTNNB1 mutations. Five-year survival was worse for patients with L1CAM expression (overall survival 46.1% vs 63.6%, P=.014, disease specific survival 63.8% vs 80.0%, P=.018). Multivariate analysis indicates L1CAM expression as an independent prognostic marker (HR 2.9, 95% CI 1.10-7.68). An in vitro spheroid invasion assay showed decreased invasion of L1CAM-expressing VSCC spindle cells after treatment with L1CAM-neutralising antibodies.

methodsParaffin-embedded tumour tissue from two cohorts (N=103 and 245) of primary VSCCs were stained for L1CAM, vimentin and E-cadherin. Patients of the first cohort were tested for human papilloma virus infection and sequenced for TP53 and CTNNB1 (β-catenin) mutations. The expression of L1CAM was correlated to clinical characteristics and patient survival.

conclusionThis is the first study to show high L1CAM-expression at the infiltrating margin of VSCC's. L1CAM-expressing VSCCs had a significantly worse prognosis compared to L1CAM-negative tumours. The highest expression was observed in spindle-shaped cells, where it might be correlated to their invasive capacity.

Indexed as

AgedBiomarkers, TumorCarcinoma, Squamous CellFemaleHumansNeoplasm Recurrence, LocalNeural Cell Adhesion Molecule L1PrognosisSurvival RateVulvar NeoplasmsBiomarkers, TumorNeural Cell Adhesion Molecule L1L1CAML1 cell adhesion moleculesquamous cell carcinomasurvivalvulvar cancer

Identifiers

PMID27028855
PMCPMC5041974
OpenAlexW2334346799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.